Friday, October 26, 2018 Daily Archives

Deal-making digest: IDT’s $80m US contract, WuXi’s strategic partership

The US National Institutes of Health (NIH) has awarded IDT Biologika a ten-year contract to make biologics and vaccines worth up to $80 million. Meanwhile, IDT Biologika has been contracted by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) – an agency of the United States Department of Health and Human Services – to provide process development, manufacturing and characterization of vaccine and biologic products. The German drug and vaccine maker will…

Merck & Co. pumping up to $16bn into biomanufacturing

Merck & Co. has upped its capital expenditure plans through 2022 to increase manufacturing capacity in areas including oncology and vaccines. At the beginning of the year, tax changes in the US led to a wealth of potential investment promises by Big Pharma looking to benefit from lower corporate rates and to repatriate cash from overseas. Merck & Co. (known as MSD outside North America) was one such firm, and in its February earnings call it announced plans to invest…